Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease

被引：0

作者：

Rosenblatt, Tatiana R. ^{[1
]}

Chiou, Carolina A. ^{[1
]}

Yoon, Michael K. ^{[1
]}

Lee, Nahyoung Grace ^{[1
]}

Wolkow, Natalie ^{[1
]}

Freitag, Suzanne K. ^{[1
]}

机构：

[1] Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA

来源：

BRITISH JOURNAL OF OPHTHALMOLOGY | 2024年

关键词：

Orbit; Inflammation; Eye Lids; Treatment Medical; Cosmesis; AGE;

D O I：

10.1136/bjo-2024-325527

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab's clinical effect since a given number of millimetres change can be of variable impact depending on patients' degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2-40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5-10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab's clinical impact.

引用

页数：3

共 50 条

[1] Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease
Rosenblatt, Tatiana R.
Chiou, Carolina A.
Yoon, Michael K.
Wolkow, Natalie
Lee, Nahyoung Grace
Freitag, Suzanne K.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (02): : 187 - 191
[2] Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease"
Kan, Aaron Y. L.
Tiong, Claudia J.
Tsoi, Amy T.
Vasanthan, Aadhavi
Rezkalla, Mina
Chan, Leo J. S.
Francis, Ian C.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (05): : 582 - 583
[3] Reply Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease"
Rosenblatt, Tatiana R.
Chiou, Carolina A.
Yoon, Michael K.
Wolkow, Natalie
Lee, Nahyoung Grace
Freitag, Suzanne K.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (05): : 583 - 583
[4] Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease
Hubschman, Sasha
Sojitra, Badal
Ghiam, Sean
Sears, Connie
Hwangbo, Nathan
Goldberg, Robert A.
Rootman, Daniel B.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (03): : 270 - 275
[5] Teprotumumab for the treatment of thyroid eye disease
Ju, Yongjing
Yang, Junyi
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (08) : 739 - 743
[6] Teprotumumab for the Treatment of Thyroid Eye Disease
Ugradar, Shoaib
Malkhasyan, Emil
Douglas, Raymond S.
ENDOCRINE REVIEWS, 2024, 45 (06) : 843 - 857
[7] Teprotumumab for the treatment of thyroid eye disease
Fallahi, Poupak
Ragusa, Francesca
Paparo, Sabrina Rosaria
Elia, Giusy
Balestri, Eugenia
Mazzi, Valeria
Patrizio, Armando
Botrini, Chiara
Benvenga, Salvatore
Ferrari, Silvia Martina
Antonelli, Alessandro
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (02) : 123 - 131
[8] Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease
Hwang, Catherine J.
Rebollo, Nicole P.
Mechels, Keegan B.
Perry, Julian D.
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2024, 263 : 152 - 159
[9] Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease
Sears, Connie M.
Azad, Amee D.
Amarikwa, Linus
Pham, Brandon H.
Men, Clara J.
Kaplan, Daniel N.
Liu, Jocelyn
Hoffman, Andrew R.
Swanson, Austin
Alyono, Jennifer
Lee, Jennifer Y.
Dosiou, Chrysoula
Kossler, Andrea L.
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 240 : 1 - 13
[10] Teprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S.
Kahaly, G. J.
Patel, A.
Sile, S.
Thompson, E. H. Z.
Perdok, R.
Fleming, J. C.
Fowler, B. T.
Marcocci, C.
Marino, M.
Antonelli, A.
Dailey, R.
Harris, G. J.
Eckstein, A.
Schiffman, J.
Tang, R.
Nelson, C.
Salvi, M.
Wester, S.
Sherman, J. W.
Vescio, T.
Holt, R. J.
Smith, T. J.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04): : 341 - 352

← 1 2 3 4 5 →